ANGPTL3 and metabolic dysfunction-associated steatotic liver disease: Furthermore, ANGPTL3 expression is elevated in the livers of NAFLD patients,149, 157 and its inhibitors have the potential to mitigate the progression of NAFLD and provide promising therapeutic approaches for NAFLD.